How Do Humira and Enbrel Work for Plaque Psoriasis?
Humira (adalimumab) and Enbrel (etanercept) are both biologic drugs that target tumor necrosis factor (TNF), a protein driving inflammation in plaque psoriasis. Humira fully blocks TNF-alpha by binding it completely, while Enbrel acts as a decoy receptor, partially neutralizing TNF-alpha along with other cytokines like lymphotoxin. This gives Humira a more targeted TNF inhibition.[1][2]
What Do Clinical Trials Show for Effectiveness?
In head-to-head data from the VISAR trial, Humira cleared skin better than Enbrel at week 12: 80% of Humira patients achieved PASI 75 (75% skin clearance) versus 61% on Enbrel, and 53% on Humira hit PASI 90 versus 22% on Enbrel. Long-term, Humira maintained higher response rates through 24 weeks. Real-world studies like Corrona psoriasis registry confirm Humira's edge in achieving clear or almost clear skin (PASI 90+).[3][4]
Humira also shows faster onset, with noticeable improvement by week 4 in trials like CHAMPION (versus methotrexate).[1]
How Do Side Effects and Safety Compare?
Both carry black-box warnings for serious infections, tuberculosis reactivation, and rare lymphoma risk due to TNF suppression. Enbrel has a slightly higher injection-site reaction rate (around 37% vs. Humira's 14%), but Humira links to more lupus-like symptoms and liver enzyme elevations in some psoriasis patients. Overall serious adverse event rates are similar (about 5-7% in trials), with no major mortality difference.[1][2][5]
| Aspect | Humira | Enbrel |
|--------|--------|--------|
| Common side effects | Upper respiratory infections, headache, rash | Injection-site reactions, sinusitis, cough |
| Rare risks | Demyelinating disorders, heart failure worsening | Similar, plus more anaphylaxis reports |
| Long-term safety | Comparable; monitored via registries | Slightly better TB screening data |
Dosing Schedules and Administration
Humira starts with an 80 mg loading dose, then 40 mg every other week via pre-filled syringe or pen. Enbrel is 50 mg weekly for 12 weeks (self-injected), then every other week. Humira's less frequent dosing improves adherence for many patients.[1][2]
Cost and Insurance Coverage Differences
Humira lists at $6,000-$7,000 per month before discounts, Enbrel around $5,000-$6,000. With biosimilars, Enbrel-equivalents like Erelzi cost 20-30% less. Patient assistance programs (e.g., Humira Complete Savings) cap copays at $5/month for eligible insured patients. Medicare Part D covers both, but step therapy often favors Enbrel first due to generics.[6]
Patent note: Humira's main U.S. patents expired in 2023, spurring biosimilars like Hadlima; Enbrel's key patent ended 2023-2024, with more biosimilars entering.[7]
Who Might Respond Better to One Over the Other?
Humira outperforms in moderate-to-severe cases needing rapid, deep clearance, per trials. Enbrel suits patients with milder disease or injection tolerance issues, and it's FDA-approved for kids as young as 4 (Humira from 8). Switch if no response after 3-6 months; about 30% of Enbrel non-responders improve on Humira.[3][4]
Guidelines (AAD/NPF) rank both as first-line biologics post-topicals/phototherapy, without strong preference.[8]
[1] https://www.humirahcp.com/psoriasis
[2] https://www.enbrel.com/psoriasis
[3] Journal of the American Academy of Dermatology (VISAR trial, 2014)
[4] Journal of Drugs in Dermatology (Corrona registry, 2019)
[5] FDA labels: Humira PI, Enbrel PI
[6] GoodRx pricing data (2024)
[7] https://www.drugpatentwatch.com/p/tradename/ENBREL and /p/tradename/HUMIRA
[8] AAD/NPF Joint Guidelines (2021)